WASHINGTON (AP) — A dispute about the size of eye drops has failed to catch the eye of the Supreme Court.
Drug companies including Allergan, Bausch & Lomb, Merck and Pfizer had asked the court to get involved in the case. The companies were sued by patients using their eye drops to treat glaucoma and other eye conditions. The high court said Monday that it won't take the case. That means a lower-court decision allowing the lawsuit to go forward will stand.
The patients said that drug companies' bottles dispense drops that are too large, leaving wasted medication running down their faces. The patients said they would pay less for their treatment if their bottles were designed to dispense smaller drops.
Companies said the patients shouldn't be able to sue in federal court.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
